Abstract The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute
respiratory syndrome coronavirus (SARS-CoV)-2, continues to cause substantial morbidity …

SARS-CoV-2 infection is benign in most individuals but, in around 10% of cases, it triggers
hypoxaemic COVID-19 pneumonia, which leads to critical illness in around 3% of cases …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection fatality rate (IFR)
doubles with every 5 y of age from childhood onward. Circulating autoantibodies …

Lung-infiltrating macrophages create a marked inflammatory milieu in a subset of patients
with COVID-19 by producing a cytokine storm, which correlates with increased lethality …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible
and virulent human-infecting coronavirus that emerged in late December 2019 in Wuhan …

Disease and accompanying inflammation are uncommon outcomes of viral infection in
humans. Clinical inflammation occurs if steady-state cell-intrinsic and leukocytic immunity to …

The immense interindividual clinical variability during any infection is a long-standing
enigma. Inborn errors of IFN-γ and IFN-α/β immunity underlying rare infections with weakly …

The vast interindividual clinical variability observed in any microbial infection—ranging from
silent infection to lethal disease—is increasingly being explained by human genetic and …

Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19
pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring …

The impacts of interferon (IFN) signaling on COVID-19 pathology are multiple, with both
protective and harmful effects being documented. We report here a multiomics investigation …